Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011;16(2):257-61.
doi: 10.3851/IMP1749.

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Sarita D Boyd  1 , Frank Maldarelli, Irini Sereti, G Laissa Ouedraogo, Catherine A Rehm, Valerie Boltz, Diana Shoemaker, Alice K Pau
Affiliations
Case Reports

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Sarita D Boyd et al. Antivir Ther. 2011.

Abstract

Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflicts of interest.

Figures

Figure 1
Figure 1. Antiretroviral regimens, HIV RNA, CD4 count, and resistance testing results through week 48 of treatment
DOT = directly observed therapy, DRV/r = darunavir plus low-dose ritonavir, EFV = efavirenz, ETR = etravirine, FTC = emtricitabine, RAL = raltegravir, TDF = tenofovir
See this image and copyright information in PMC

References

    1. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8:1–8. - PubMed
    1. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24:1203–1212. - PubMed
    1. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174–2180. - PubMed
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; [Accessed 18 October 2010]. (Updated 1 December 2009).
    1. Baroncelli S, Villani P, Weimer LE, et al. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother. 2010;44:838–843. - PubMed

Publication types

MeSH terms